- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07471113
Mobile App-Supported HPV and Breast Cancer Awareness Program
March 11, 2026 updated by: NİHAN TÜRKOĞLU, Ataturk University
The Impact of a Mobile App-Supported Human Papilloma Virus and Breast Cancer Program on HPV Literacy and Breast Cancer Screening Beliefs
The goal of this study is to learn about the impact of a mobile application-supported education program on women's HPV literacy and their beliefs regarding breast cancer screening. The main questions it aims to answer are:
- Does a mobile application-supported program increase HPV literacy levels among women?
- Does this intervention strengthen women's positive beliefs and attitudes toward breast cancer screening? Researchers will examine how this holistic, health-based intervention changes participants' awareness and screening perspectives.
Participants will:
- Use a mobile application designed to provide education on HPV and breast cancer
- Complete surveys regarding their HPV knowledge and breast cancer screening beliefs before and after the program
- Engage with health-related content through the mobile platform for the duration of the study.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study aims to evaluate the effect of a mobile application-supported Human Papillomavirus (HPV) and breast cancer program on HPV literacy and breast cancer screening beliefs among women attending primary health care services.
Study Type
Interventional
Enrollment (Actual)
70
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Erzurum, Turkey (Türkiye), 25240
- Ataturk University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- -Women aged 30-65 years
- -Literate (able to read and write)
- -Able to understand and speak Turkish
- -Able to use a smartphone
- -Willing to use the mobile application during the study period and consent to data sharing
Exclusion Criteria:
- Having undergone regular breast cancer (mammography) and/or cervical cancer (Pap smear/HPV DNA test) screening within the last 3 years, in accordance with national screening guidelines
- Previous diagnosis of any cancer
- Neurological conditions affecting cognitive function (e.g., dementia, Alzheimer's disease) or physical/psychiatric conditions that would seriously limit study participation and mobile app use
- Pregnancy or breastfeeding
- Participation in another health-related research study during the study period
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Mobil-App
A mobile application will be implemented as an intervention targeting this group.
|
A mobile application will be implemented for this group.
|
|
No Intervention: Control
No intervention will be made against this group.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in HPV literacy (HPV-LS total score) from baseline (pretest) to post-intervention (posttest) compared between the Mobile Application-Supported Education Group and the Control Group.
Time Frame: 12 MONTH
|
The primary outcome is the change in participants' HPV literacy as measured by the HPV Literacy Scale (HPV; 24 items, 5-point Likert).
Total scores range from 24 to 120, with higher scores indicating higher HPV literacy.
The outcome will be assessed at baseline (pretest) and post-intervention (posttest) and compared between groups.
|
12 MONTH
|
|
Change in breast cancer screening beliefs (Breast Cancer Screening Beliefs Scale total score and/or subscale scores) from baseline to post-intervention compared between groups.
Time Frame: 12 MONTH
|
Breast Cancer Screening Beliefs: The primary outcome is the change in breast cancer screening beliefs measured by the Breast Cancer Screening Beliefs Scale (13 items, 5-point Likert; transformed scoring 0-100).
Higher scores indicate more positive screening beliefs (more favorable attitudes/knowledge and fewer perceived barriers).
The outcome will be assessed at baseline (pretest) and post-intervention (posttest) and compared between groups.
|
12 MONTH
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Nihan Türkoğlu, Ataturk University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 2, 2025
Primary Completion (Actual)
December 25, 2025
Study Completion (Actual)
January 2, 2026
Study Registration Dates
First Submitted
November 26, 2025
First Submitted That Met QC Criteria
March 11, 2026
First Posted (Actual)
March 13, 2026
Study Record Updates
Last Update Posted (Actual)
March 13, 2026
Last Update Submitted That Met QC Criteria
March 11, 2026
Last Verified
March 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Uterine Diseases
- Genital Diseases, Female
- Genital Neoplasms, Female
- Skin Diseases
- Breast Diseases
- Uterine Cervical Diseases
- Uterine Neoplasms
- Skin and Connective Tissue Diseases
- Breast Neoplasms
- Uterine Cervical Neoplasms
Other Study ID Numbers
- B.30.2.ATA.0.01.00/187 etik
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
Oncoliq US IncRecruitingBreast Cancer Female | Breast Cancer Detection | Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Breast Cancer With Low to Intermediate HER2 Expression | Breast Cancer - Female | Breast Cancer (Early Breast Cancer) | Breast Cancer - Ductal Carcinoma in Situ (DCIS) | Breast Cancer - Infiltrating...Argentina
-
University of California, IrvineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast CancerUnited States
-
Joseph Baar, MD, PhDCompletedBreast Cancer | Stage I Breast Cancer | Inflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast CancerUnited States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Case Comprehensive Cancer CenterNational Institute on Minority Health and Health Disparities (NIMHD)CompletedCancer Survivor | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
Clinical Trials on mobile application
-
Marta MarciniakRecruiting
-
Mississippi State UniversityCompleted
-
Mississippi State UniversityAssociation for contextual behavioral scienceCompletedHealth-Related BehaviorUnited States
-
George Washington UniversityMedia RezCompleted
-
University of ReginaCompletedStress | Dementia | Caregiver BurdenCanada
-
University Hospitals Cleveland Medical CenterCompleted
-
Seda ÇETİN AVCIActive, not recruiting
-
University of CadizCompleted
-
Boston Medical CenterBoston Medical Center Food KitchenWithdrawnDiabetes Mellitus, Type 2 | Pre DiabetesUnited States
-
Instituto de investigación e innovación biomédica...Completed